News · More Oncolys Biopharma, Inc. news

Oncolys Biopharma, Inc. TSE:4588

Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

Published June 8, 2026 at 6:30 a.m. UTC

Source: TDnet

Oncolys Biopharma, Inc. (4588) Press Release

View Attachment